Acuta Capital Partners, LLC is an SEC-registered investment adviser based in Redwood City, CA that reports managing 2 hedge funds on Form ADV. It reports $172.5 million in regulatory assets under management. Its private funds, of all types, hold $172.5 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +24.9% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +188.3% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $172.5 millionForm ADV Item 5.F
- Gross assets of private funds
- $172.5 millionAll private fund types, Form ADV
- Hedge funds managed
- 22 private funds in total
- Employees
- 4Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 158869
- Latest Form ADV
- 06/30/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +10.0% | +14.8% |
| Q1 2026 | +13.6% | -4.6% |
| Q4 2025 | +62.9% | +2.4% |
| Q3 2025 | +47.1% | +7.8% |
| Q2 2025 | +9.9% | +10.4% |
| Q1 2025 | -16.5% | -4.5% |
| Q4 2024 | -10.6% | +2.1% |
| Q3 2024 | +17.4% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Largest disclosed holdings
- Praxis Precision Medicines I$27.7 million
- Whitehawk Therapeutics Inc$21.5 million
- Tango Therapeutics Inc$12.2 million
- 869367201$9.0 million
- Arrivent Biopharma Inc$7.6 million
- 4D Molecular Therapeutics In$6.8 million
- Bright Minds Biosciences Inc$6.5 million
- Ocular Therapeutix Inc$5.2 million
- Erasca Inc$4.9 million
- Surrozen Inc$4.5 million
As of 2026-06-30, from 13F filing by Acuta Capital Partners, LLC.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures